GPCR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
118.6M
+32.7%
89.4M
+750.5%
-13740000
-118.6%
73.8M
+4.7%
70.5M
R&D
100.1M
+50.4%
66.5M
-3.2%
68.7M
+16.4%
59.0M
+7.8%
54.7M
SG&A
18.6M
-18.8%
22.9M
+30.2%
17.6M
+18.7%
14.8M
-6.0%
15.7M
Operating Income
-118630000
-32.7%
-89379000
-750.5%
13.7M
+118.6%
-73787000
-4.7%
-70451000
EBITDA
-118079000
-33.0%
-88803000
-727.5%
14.2M
+119.3%
-73431000
-4.7%
-70160000
Net Income
-106159000
-39.7%
-75968000
-330.2%
33.0M
+150.2%
-65712000
-6.6%
-61661000
EPS (Basic)
$-0.49
-40.0%
$-0.35
-305.9%
$0.17
+145.9%
$-0.37
-2.8%
$-0.36
EPS (Diluted)
$-0.49
-40.0%
$-0.35
-305.9%
$0.17
+145.9%
$-0.37
-2.8%
$-0.36
Shares (Diluted)
218.0M
+0.3%
217.3M
+14.3%
190.2M
+8.4%
175.5M
+1.6%
172.6M
Structure Therapeutics Inc. American (GPCR) โ€” Financials